PFE

Pfizer, Inc.

52.43
USD
2.93%
52.43
USD
2.93%
38.93 61.71
52 weeks
52 weeks

Mkt Cap 292.46B

Shares Out 5.58B

Chat
Send me real-time posts from this site at my email

CDC, FDA in discussions for second COVID booster for those under 50: Walensky

The CDC is "in conversations" with the U.S. FDA about expanding eligibility for a second COVID-19 vaccine for those under the age of 50, CDC Director Rochelle Walensky said Wednesday. Speaking at a White House COVID-19 Response Team press briefing, Walensky reiterated the importance of those in that demographic to get a first booster if they have not done so yet to prevent severe disease and hospitalization. Currently, a second booster is only available to individuals 50 and over, or those under that age with certain medical conditions. The CDC recommends either the Moderna (NASDAQ:MRNA) or Pfizer (NYSE:PFE)/BioNTech (NASDAQ:BNTX) mRNA vaccines for boosters. Walensky expressed concern that populations more vulnerable to COVID have not received a booster. She noted that 62% of those between the ages of 50 and 64 have not received a vaccine dose in the last six months; the figure is 57% for those 65 and older. The FDA on Tuesday authorized the use of the Pfizer (PFE)/BioNTech (BNTX) shot as a booster for children 5-11 years old.

Welcome! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue